There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amphastar Pharmaceuticals (AMPH – Research Report) and Erasca (ERAS – Research Report) with bullish sentiments.
Amphastar Pharmaceuticals (AMPH)
Capital One Financial analyst Tim Chiang maintained a Buy rating on Amphastar Pharmaceuticals today and set a price target of $70.00. The company’s shares closed last Wednesday at $42.21.
According to TipRanks.com, Chiang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Amphastar Pharmaceuticals is a Moderate Buy with an average price target of $62.60, implying a 46.1% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $71.00 price target.
See today’s best-performing stocks on TipRanks >>
Erasca (ERAS)
In a report released today, Naureen Quibria from Capital One Financial reiterated a Buy rating on Erasca, with a price target of $8.00. The company’s shares closed last Wednesday at $2.15.
According to TipRanks.com, Quibria is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Erasca with a $7.50 average price target, which is a 244.0% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMPH:
